Our research in this area mainly relates to mitochondrial malfunction, leading to disease in humans and animals, including myopathies, neuropathies, metabolic diseases, and infertility. Substantial evidence suggests it may not always be the faulty mitochondria per se that cause the disease but a disrupted interaction/ communication/ signalling between the mitochondria and the nucleus. This evidence is largely based on experiments in animals and on the observation that not all people with a particular mitochondrial mutation develop the disease – some nuclear backgrounds seem to cope with faulty mitochondrial mutations. We have developed experimental systems, so-called Drosophila mitolines, that allow us to quantify the health and fitness effects of different mitochondrial-nuclear matches. The resulting data have substantial bearing on the recently introduced mitochondrial replacement therapy, where nuclear DNA is placed into unrelated mitochondrial surroundings.
See our publications on this topic:
Dobler R, Dowling DK, Morrow EH & Reinhardt K. 2018. A systematic review and meta-analysis reveals pervasive effects of germline mitochondrial replacement on components of health. Human Reproductive Update. Link
Grunau C, Voigt S, Dobler R, Dowling DK, Reinhardt K. 2018. The cytoplasm affects the epigenome in Drosophila melanogaster. Epigenomes. Link
Morrow et al. 2015. Risks inherent to mitochondrial replacement. EMBO Reports. link to pdf
Dobler et al. 2014. A meta-analysis of the strength and nature of cytoplasmic genetic effects. Journal of Evolutionary Biology 27: 2021-2034. link to pdf.
Reinhardt et al. 2013. Mitochondria replacement, Evolution, and the Clinic. Science 341: 1345-1346. link to pdf
Here is some coverage. Note, that not everyone is happy with our conclusions:
- recommended by Faculty1000
- read the BBC’s report about it
- read the New Scientist’s report about it
- read the Laborjournal’s editorial about it
- See here the statement by British government authority who have, within hours, dismissed our findings. More to come…
- The article has been used as evidence in a debate in the British Parliament and a meeting of the Food and Drug Association (FDA)